Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 19/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20261979 | 1.00 | IRAK4 (0.62) | IRAK4PDE4BPDE7A | |
| SCHEMBL22024780 | 0.93 | IRAK4 (0.52) | IRAK4PDE4BPDE7A | |
| SCHEMBL20273952 | 0.87 | PDE4B (0.55) | IRAK4PDE4BPDE7A | |
| SCHEMBL16595164 | 0.86 | IRAK4 (0.56) | IRAK4PDE4B | |
| SCHEMBL20273950 | 0.86 | IRAK4 (0.56) | IRAK4PDE4B | |
| SCHEMBL20273821 | 0.86 | PDE4B (0.60) | IRAK4PDE4BPDE7A | |
| SCHEMBL28667200 | 0.86 | IRAK4 (0.47) | IRAK4PDE4BPDE7A | |
| SCHEMBL20273858 | 0.83 | IRAK4 (0.67) | IRAK4PDE4B | |
| SCHEMBL28670948 | 0.83 | IRAK4 (0.45) | IRAK4PDE4BPDE7A | |
| SCHEMBL20273857 | 0.83 | IRAK4 (0.67) | IRAK4PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988482-B2 | IRAK4 inhibitor and use thereof | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2021-04-27 | — | — | US | disclosed |
| CN-107531725-B | IRAK4 inhibitor and application thereof | 北京韩美药品有限公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3336091-B1 | IRAK4 INHIBITOR AND USE THEREOF | BEIJING HANMI PHARMACEUTICAL CO LTD (CN) | 2020-12-02 | — | — | EP | disclosed |
| US-20200062775-A1 | IRAK4 INHIBITOR AND USE THEREOF | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3336091-A1 | IRAK4 INHIBITOR AND USE THEREOF | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2018-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988482-B2 | IRAK4 inhibitor and use thereof | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885PDE4B 490/4885PDE7A 959/4885 |
| US-20200062775-A1 | IRAK4 INHIBITOR AND USE THEREOF | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885PDE4B 490/4885PDE7A 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.